-
公开(公告)号：JP5368991B2
公开(公告)日：2013-12-18
申请号：JP2009531112
申请日：2008-09-03
申请人： 株式会社日本ステントテクノロジー , 学校法人東海大学 , トーヨーエイテック株式会社 , 博夫 岩田
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8 : 2 to 3 : 7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80 % by weight of the polymer being less than 20 % by weight.
-
-
公开(公告)号：JP2010264253A
公开(公告)日：2010-11-25
申请号：JP2010134943
申请日：2010-06-14
申请人： Hiroo Iwata , Japan Stent Technology Co Ltd , Tokai Univ , Toyo Advanced Technologies Co Ltd , トーヨーエイテック株式会社 , 学校法人東海大学 , 博夫 岩田 , 株式会社日本ステントテクノロジー
发明人： KOMURA IKUO , KIN TEIGYOKU , YAMASHITA SHUZO , IWATA HIROO , MOCHIZUKI AKIRA
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： PROBLEM TO BE SOLVED: To provide a stent carrying a vascular intimal hyperplasia inhibitor, which does not inhibit proliferation of endothelial cells, which stent is capable of releasing the drug in controlled manner. SOLUTION: The stent includes a stent body of a cylindrical configuration, a first coated layer coating the outer surface of the stent body, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban), which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. The second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80 wt.% of the polymer being less than 20 wt.%. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译： 要解决的问题：为了提供一种携带血管内膜增生抑制剂的支架，其不抑制内皮细胞的增殖，该支架能够以受控的方式释放药物。 解决方案：支架包括圆柱形构造的支架主体，涂覆支架主体的外表面的第一涂层和基本上完全覆盖第一涂层的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在8： 2到3：7。 第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，药物与聚合物的80重量％的重量组成比小于20重量％。 版权所有（C）2011，JPO＆INPIT
-
公开(公告)号：JP4398124B2
公开(公告)日：2010-01-13
申请号：JP2001365934
申请日：2001-11-30
申请人： 和田 冨美夫 , 博夫 岩田 , 株式会社日本ステントテクノロジー
摘要： PROBLEM TO BE SOLVED: To provide a catheter which holds pharmacologically active substances before arriving of the distal end of the catheter at a lesion and can rapidly release the pharmacologically active substances in the lesion. SOLUTION: A hydrogel layer having the phase transition temperature at which the layer swells by making phase transition lower than the temperature of the human body, e.g. ≤36°C, and containing the pharmacologically active substances, more preferably the hydrogel layer consisting of a copolymer essentially consisting of isopropyl acrylamide is formed on the balloon of the balloon catheter. COPYRIGHT: (C)2003,JPO
-
公开(公告)号：JP5636451B2
公开(公告)日：2014-12-03
申请号：JP2013021873
申请日：2013-02-07
申请人： 株式会社日本ステントテクノロジー , 学校法人東海大学 , 岩田 博夫 , 博夫 岩田
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
-
公开(公告)号：JP5636450B2
公开(公告)日：2014-12-03
申请号：JP2013021872
申请日：2013-02-07
申请人： 株式会社日本ステントテクノロジー , 学校法人東海大学 , 岩田 博夫 , 博夫 岩田
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
-
公开(公告)号：JP5369056B2
公开(公告)日：2013-12-18
申请号：JP2010134943
申请日：2010-06-14
申请人： 株式会社日本ステントテクノロジー , 学校法人東海大学 , 博夫 岩田
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8 : 2 to 3 : 7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80 % by weight of the polymer being less than 20 % by weight.
-
公开(公告)号：JP4294482B2
公开(公告)日：2009-07-15
申请号：JP2003544199
申请日：2002-11-14
申请人： 協和発酵キリン株式会社 , 博夫 岩田 , 芳樹 笹井
IPC分类号： C12N5/10 , A61K35/12 , A61K35/48 , A61K38/00 , A61K38/17 , A61P17/00 , A61P25/00 , A61P25/16 , A61P25/28 , A61P43/00 , C07K14/47 , C12N5/071 , C12N5/073 , C12N15/09 , C12N15/12 , G01N33/50 , G01N33/68
CPC分类号： G01N33/5073 , A61K35/12 , A61K35/48 , A61K38/1709 , C12N5/0603 , C12N5/0619 , C12N2501/415 , C12N2501/90 , C12N2501/91 , C12N2502/13 , C12N2503/02 , C12N2506/02 , G01N33/5008 , G01N33/5023 , G01N33/5058 , G01N33/6896
-
公开(公告)号：JP4219955B2
公开(公告)日：2009-02-04
申请号：JP2006528933
申请日：2005-07-06
申请人： 協和発酵キリン株式会社 , 博夫 岩田 , 芳樹 笹井
IPC分类号： C12N5/0793
CPC分类号： C12N5/0619 , C12N2500/38 , C12N2506/02
-
公开(公告)号：JP2008044915A
公开(公告)日：2008-02-28
申请号：JP2006224170
申请日：2006-08-21
申请人： Yoshiaki Hirano , Hiroo Iwata , 博夫 岩田 , 義明 平野
发明人： HIRANO YOSHIAKI , IWATA HIROO
摘要： PROBLEM TO BE SOLVED: To provide a VEGF mimetic peptide composite having an excellent endothelial cell growth activity.
SOLUTION: The peptide composite is two or more peptide chains bonded to a water soluble polymer or its derivative and the peptide chain is at least one kind selected from the peptide chains represented by (1) Try-Pro-Asp-Glu-Ile-Glu-Try-Ile, (2) Cys-Asn-Asp-Glu-Gly-Leu-Glu-Cys, and (3) Ile-Met-Arg-Ile-Lys-Pro-His-Glu. An endothelial cell growth promotor contains the peptide composite as an active ingredient.
COPYRIGHT: (C)2008,JPO&INPIT摘要翻译： 待解决的问题：提供具有优异内皮细胞生长活性的VEGF模拟肽复合物。 肽复合物是两个或更多个与水溶性聚合物或其衍生物结合的肽链，肽链是选自由（1）Try-Pro-Asp-Glu- Ile-Glu-Try-Ile，（2）Cys-Asn-Asp-Glu-Gly-Leu-Glu-Cys和（3）Ile-Met-Arg-Ile-Lys-Pro-His-Glu。 内皮细胞生长促进剂含有作为活性成分的肽复合物。 版权所有（C）2008，JPO＆INPIT
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.035 秒)
